Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Linagliptin Effects on Inflammation and Insulin Resistance in Obese T2D
NCT02372630Phase 4Completed
- Sponsor
- University at Buffalo
- Start
- May 2014
- Primary completion
- Feb 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of linagliptin in type 2 diabetes mellitus (T2DM), sponsored by University at Buffalo. Started May 2014; status: completed.
02
Drugs
linagliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02372630.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02372630.